Group 1 - The company expects consolidated revenue for the period ending mid-2025 to be no less than RMB 500 million, representing an increase of at least approximately 387% compared to the revenue of about RMB 103 million for the six months ending June 30, 2024 [1] - The company anticipates a turnaround from a net loss of RMB 1.238 billion for the six months ending June 30, 2024, to a net profit of no less than RMB 50 million for the mid-2025 period [1] - The company also expects an adjusted net profit (non-IFRS) of no less than RMB 120 million for the mid-2025 period, compared to an adjusted net loss (non-IFRS) of RMB 251 million for the six months ending June 30, 2024 [1] Group 2 - The expected improvement in financial performance for mid-2025 is primarily due to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + robotics" technology [2] - The company received an upfront payment of USD 51 million, which has been recognized as revenue for the mid-2025 period and significantly contributes to the company's revenue during the reporting period [2] - According to the agreement with DoveTree, the company is entitled to receive further payments, which will be recognized as revenue in batches in the future [2]
晶泰控股(02228)发盈喜 预计中期综合收益同比增加至少约387%